Contact About Find a doctor Careers The Alfred Foundation For staff

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Clear filter

604 clinical trials found

Clinical trials

The SMART-AF study

The SMART-AF study (ACTRN12625000481471)

Currently recruiting

The STOP-MED CTRCD Trial

A Multi-Centre Non-Inferiority Randomized Controlled Trial of STOPping Cardiac MEDications in Patients with Normalized Cancer Therapy Related Cardiac Dysfunction: The STOP-MED CTRCD Trial (NCT06183437)

Currently recruiting

The TA Trial

Impact of Total Arterial Revascularisation in Coronary Artery Surgery on Angiographic and Clinical Outcomes (ACTRN12623000864628)

Currently recruiting

Tioga

Evaluation of Safety and Feasibility of the Tioga TMVR System for Treatment of Mitral Regurgitation (NCT06038838)

Currently recruiting

TITANIA

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations. (NCT05158387)

No longer recruiting

TMS in PMDD

Theta Burst Transcranial Magnetic Stimulation to Treat Premenstrual Dysphoric Disorder – An Open Label Pilot Study (ACTRN12622000909729)

Currently recruiting

TOSCCAA - TXA

Treatment of Stroke Recurrence in CAA with Tranexamic Acid (ACTRN12624001477516)

This study is looking at whether a medicine called tranexamic acid can help reduce the risk of intracranial haemorrhage (ICH) recurrence in Cerebral Amyloid Angiopathy (CAA).

Currently recruiting

TRAILBLAZER-ALZ 2

Assessment of Safety, Tolerability, and Efficacy of LY3002813 in Early Symptomatic Alzheimer’s Disease (NCT04437511)

Currently recruiting

TRAILBLAZER-ALZ 5

Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (NCT05508789)

Currently recruiting

TRANQUILLO

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO (NCT05583526)

No longer recruiting

TRANSFORM-2

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) (NCT04468984)

No longer recruiting

Traveller WP45722

Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

The purpose of this pre-screening study is to identify people who may be eligible for future clinical trials that test new drugs for Alzheimer’s disease (AD). Participants will be asked to perform a memory test and give a blood sample for the assessment of pTau217 blood biomarker that has been developed to help identify people who are likely to have AD. Participants will not receive any medication or therapeutic intervention in this study.

Currently recruiting

TRICS-IV

TRICS IV: Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery. An international, multi-centre, randomized controlled trial to assess (NCT04754022)

Currently recruiting

TRIGS

Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial (NCT04192435)

Currently recruiting

TRITON

A Feasibility Trial of Tranexamic Acid for Necrotising Soft-Tissue Infections (ACTRN12621001423808)

Currently recruiting

TRIUMPH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index =27 kg/m^2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease. (NCT06383390)